Low objective response and high toxicity to single-agent mitotane in patients with metastatic adrenocortical carcinoma (ACC): A 25 year experience at MSKCC

Autor:	Scott R. Gerst, Leonard B. Saltz, Seth S. Katz, Diane Lauren Reidy, Betty Y Lung, Kelly Olino, Emily Valentino, Brian R. Untch, Nitya Raj, Vivian E. Strong
Rok vydání:	2015
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Metastatic Adrenocortical Carcinoma Testosterone (patch) Disease Surgery stomatognathic diseases Internal medicine Toxicity medicine Mitotane Single agent In patient business Objective response medicine.drug
Zdroj:	Journal of Clinical Oncology. 33:4105-4105
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2015.33.15_suppl.4105
Popis:	4105 Background: ACC is a rare but devastating disease, with short life expectancy in the setting of metastatic, unresectable disease. Mitotane, an oral adrenocorticolytic agent, is often used as a systemic treatment though its therapeutic window is narrow. We retrospectively assessed outcomes of patients (pts) with metastatic ACC who received single-agent mitotane therapy to determine treatment toxicities and effectiveness. Methods: In this retrospective IRB-approved study, we identified 35 pts with metastatic ACC treated with single-agent mitotane at MSKCC from 3/15/1989-9/18/2014. All pts had follow-up at MSKCC and all imaging was reviewed according to RECIST 1.1 by reference radiologists. We reviewed pt demographics, clinical symptoms, toxicity (based on CTCAE Version 4), and treatment outcomes. Results: 35 pts were identified with mean age of 53 years (range, 23-87), 60% female. 18/35 tumors (51%) were functional: estradiol (n = 1), cortisol (n = 12), testosterone (n = 3), or both testosterone and co...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::eafa11186a7eebc2768a7b2653eb1d9b https://doi.org/10.1200/jco.2015.33.15_suppl.4105 Zobrazit plný text záznamu